Tag: MindMed - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

Post published:April 5, 2021
Post category:Press Release

MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with the SEC under MJDS

MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with the SEC under MJDS

Post published:March 30, 2021
Post category:Press Release

MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD ($203 million CAD) to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform

MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD ($203 million CAD) to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform

Post published:March 30, 2021
Post category:Press Release

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board

Post published:March 29, 2021
Post category:Press Release

MindMed Announces Inclusion in FTSE Russell Indexes

MindMed Announces Inclusion in FTSE Russell Indexes

Post published:March 22, 2021
Post category:Press Release

MindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes Financing of CAD $19.5m (USD $15.4m)

MindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes Financing of CAD $19.5m (USD $15.4m)

Post published:March 9, 2021
Post category:Press Release

MindMed Announces C$19.5 Million Bought Deal Private Placement Offering

MindMed Announces C$19.5 Million Bought Deal Private Placement Offering

Post published:March 8, 2021
Post category:Press Release

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

Post published:February 26, 2021
Post category:Press Release

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company

Post published:February 18, 2021
Post category:Press Release

MindMed’s LSD Neutralizer Study Begins

MindMed’s LSD Neutralizer Study Begins

Post published:February 17, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.